Select Page
PARP Inhibition in Ovarian Cancer: Integrating the Science, the Clinical Data, and the Patient Voice to Enhance Care

This webcast is no longer certified for credit.

PARP Inhibition in Ovarian Cancer: Integrating the Science, the Clinical Data, and the Patient Voice to Enhance Care

An Independent Satellite Symposium held during the 2017 Annual Meeting on Women’s Cancer

OVERVIEW

Due to the volume of research regarding the use of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with recurrent ovarian cancer, clinicians need expert guidance to use current and emerging PARP inhibitors and companion diagnostics safely and effectively. This webcast will evaluate novel approaches to using PARP inhibitors in patients with ovarian cancer, and review emerging data and guidance regarding its application in practice.

 

TARGET AUDIENCE

The target audience for this activity is gynecologic oncologists, medical oncologists and other clinicians who treat patients with ovarian cancer.

 

LEARNING OBJECTIVES

After completing this activity, participants should be better able to:

  • Formulate strategies to use genetic testing appropriately in patients with ovarian carcinoma
  • Assess the rationale for targeting PARP in patients with ovarian cancer and BRCA mutations, given the role of PARP in DNA repair
  • Interpret the clinical significance of emerging safety and efficacy data for available and novel PARP inhibitors and companion diagnostics
  • Evaluate the patient perspective on treatment with PARP inhibitors and the role of shared decision making in treatment selection
  • Plan strategies to prevent and manage side effects of PARP inhibition

 

PRESENTATION TOPICS

Slides are available to download throughout the webcast

The Rationale for and Logistics of BRCA Testing
Thomas Herzog, MD

The Rationale for PARP Inhibition in Ovarian Cancer
Ursula A. Matulonis, MD

Assessing Currently Available and Emerging PARP Inhibitors
Robert L. Coleman, MD, FACOG, FACS

PARP Inhibitors: A Patient’s Perspective

Preventing and Managing Adverse Events of PARP Inhibitors
Shannon N. Westin, MD, MPH, FACOG

 

METHOD OF PARTICIPATION

There are no fees for participating in and receiving CME credit for this activity.

 

CONTINUING EDUCATION

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

ACCME Commendation logo

 

SUPPORT

Educational grant support provided by AstraZeneca, Clovis Oncology, Myriad Genetic Laboratories, Inc., and Tesaro, Inc.
 

HARDWARE/SOFTWARE REQUIREMENTS

Below are the requirements to access online activities:

  • Supported operating systems: Windows 7, Windows 8, Windows 10, iPad iOS 9+, and Mac OS X
  • Supported Browsers: PC – Chrome, Edge, Firefox, and Internet Explorer 11. Mac – Chrome, Firefox, and Safari. iPad – Safari
  • This activity is best experienced with a high-speed Internet connection, such as T1, cable, DSL, etc.
  • Javascript must be enabled to view this activity. Need help? Go to – www.enable-javascript.com

 

CHAIR

Robert L. Coleman, MD, FACOG, FACS
The University of Texas
MD Anderson Cancer Center
Houston, Texas

FACULTY

Thomas Herzog, MD
University of Cincinnati
Cincinnati, Ohio

Ursula A. Matulonis, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Shannon N. Westin MD, MPH, FACOG
The University of Texas
MD Anderson Cancer Center
Houston, Texas

DISCLOSURE AND CONTINUING EDUCATION INFORMATION

Robert L. Coleman, MD, FACOG, FACS

Consultant Fees: AbbVie Inc., Debiopharm Group, Genmab A/S, ImmunoGen, Inc., Merck Sharpe & Dohme Corp., Merrimack Pharmaceuticals, Inc., Millennium Pharmaceuticals, Perthera, Verastem, Inc.

Speakers’ Bureau: AstraZeneca, CancerNet, Roche

Advisory Board: AstraZeneca, Bayer AG, Cerulean Pharma Inc., Clovis Oncology, Eisai-Morphotek, GamaMabs, Genentech, Incyte Corporation, Janssen Global Services, LLC, Novocure, Pfizer Inc, Roche, Vertex Pharmaceuticals Incorporated

Grants/Research Support: Array BioPharma, AstraZeneca, Clovis Oncology, EMD Serono, Inc. Gradalis, Janssen Global Services, LLC, Merck & Co., Inc.

 
Thomas Herzog, MD

Consultant Fees, Advisory Board: AstraZeneca, Clovis Oncology, Johnson & Johnson Services, Inc., Roche, TESARO, Inc.

 
Ursula A. Matulonis, MD

Consultant Fees: AstraZeneca, ImmunoGen, Inc.

Advisory Board: AstraZeneca, Clovis Oncology, Eli Lilly and Company, Genentech/Roche

 
Shannon N. Westin MD, MPH, FACOG

Consultant Fees: AstraZeneca, Casdin Capital

Speakers’ Bureau: Medscape

Advisory Board: ASCO Leadership Development, Clovis Oncology, Genentech, Medivation, Inc., Aspira Labs, A Vermillion Company

Grants/Research Support: AstraZeneca, Critical Outcomes Technology, Inc. (COTI), Novartis

 

PROVIDER & DISCLOSURE STATEMENTS

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

 

DISCLOSURE OF OFF-LABEL USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Bio Ascend does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of Bio Ascend. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education, and Bio Ascend

ccr-logobioascend-logo-v2

Copyright © 2018 Bio Ascend LLC

Bio Ascend LLC
980 N Michigan Avenue, Suite 1400
Chicago, IL 60611
(p)773-304-5019
(f)312-277-6893 | info@bioascend.com | cme@bioascend.com | program@bioascend.com

Bio Ascend LLC observes pharmaceutical industry compliance and regulatory guidelines.